1226895-20-0

Basic information

• Product Name: ATB 346
• Synonyms: ATB 346;ABT-346;6-Methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(aminothioxomethyl)phenyl ester;6-Methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(aminothioxomethyl)phenyl ester ATB 346;ATB 346 6-Methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(aminothioxomethyl)phenyl ester;ATB-346, >=98%;ATB 346,1226895-20-0
• CAS NO: 1226895-20-0
• Molecular Formula: C21H19NO3S
• Molecular Weight: 365.44546
• Product Categories: Inhibitors
• Mol File: 1226895-20-0.mol

Chemical Properties

• Boiling Point: 561.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.261±0.06 g/cm3(Predicted)
• Solubility: insoluble in EtOH; insoluble in H2O; ≥18.27 mg/mL in DMSO
• PKA: 12.37±0.29(Predicted)
• CAS DataBase Reference: ATB 346(CAS DataBase Reference)
• NIST Chemistry Reference: ATB 346(1226895-20-0)
• EPA Substance Registry System: ATB 346(1226895-20-0)

Safety Data

• Hazardous Substances Data: 1226895-20-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ATB 346 is used as an anti-inflammatory agent for reducing inflammation and pain. It is particularly effective in decreasing prostaglandin E2 (PGE2) production in inflammatory exudates, which contributes to its anti-inflammatory action.
Used in Orthopedics:
ATB 346 is used as an analgesic for managing pain, particularly in conditions like arthritis. It has been shown to reduce paw edema in a mouse model of zymosan-induced arthritis, indicating its potential use in treating joint pain and inflammation.
Used in Oncology:
ATB 346 is used as an anti-cancer agent for inhibiting the proliferation of A375 melanoma cells and inducing apoptosis at a concentration of 100 μM. Its anti-cancer properties make it a promising candidate for the development of novel cancer therapies.
Used in Gastroenterology:
ATB 346 is used as a treatment for gastric ulcers, as it has been shown to reduce the size of acetic acid-induced gastric ulcers in mice when administered at a dose of 60 μmol/kg. This suggests its potential use in protecting the gastrointestinal tract and promoting ulcer healing.
Used in Neurology:
ATB 346 is used as a neuroprotective agent for improving motor function in a mouse model of spinal cord injury when administered at a dose of 30 μmol/kg. Its neuroprotective properties indicate its potential use in treating neurological disorders and injuries.

references

[1] wallace j l, caliendo g, santagada v, et al. markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (atb-346). british journal of pharmacology, 2010, 159(6): 1236-1246.

Upstream product

• 25984-63-8 4-hydroxythiobenzamide 
• 22204-53-1 (2S)-2-(6-methoxy(2-naphthyl))propanoic acid 
• 1000700-40-2 4-carbamoyl-phenyl 2-(2-methoxy-naphthalen-6-yl)-propanoate 

Relevant articles and documents

COMPOUNDS FOR THIOL-TRIGGERED COS AND/OR H2S RELEASE AND METHODS OF MAKING AND USING THE SAME

Disclosed herein are embodiments of a compound that is capable of releasing COS and/or H2S upon reaction with a thiol-containing compound. The compound embodiments also can produce a detectable signal (e.g., a fluorescent signal) substantially concomitantly with COS and/or H2S release and/or can release an active agent, such as a therapeutic agent. Methods of making and using the compound embodiments also are disclosed.

Syntheses, toxicities and anti-inflammation of H2S-donors based on non-steroidal anti-inflammatory drugs

Three series of H2S donors based on NSAIDs were synthesized and characterized by 1H-NMR, IR and ESI-HRMS. The H2S-release abilities of all compounds were evaluated in the presence of TECP or cysteine. The results show all

HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen